O112 : HBsAg clearance after addition of 48 weeks of pegifn in HBeAg negative CHB patients on nucleos(T)ide therapy with undetectable hbvdna for at least one year: final results from ANRS-HB06 pegan study: multicenter randomized controlled phase III trial

  M. Bourlière ¹ AuthorId : 421766
Author

  P. Rabiega AuthorId : 1175947
Author

  N. Ganne-Carrie AuthorId : 731032
Author

  L. Serfaty ² AuthorId : 421783
Author

  P. Marcellin ³ AuthorId : 421754
Author

  N. Pouget ^{4, 5} AuthorId : 90603
Author

  D. Guyader ^{6, 7} AuthorId : 948267
Author

  C. Hezode ⁸ AuthorId : 421760
Author

  Maurice Picon AuthorId : 471807
Author

  X. Causse AuthorId : 524558
Author

  V. Leroy AuthorId : 208541
Author

  J. P. Bronowicki AuthorId : 1175948
Author

  G. Riachi AuthorId : 421774
Author

  I. Rosa AuthorId : 914706
Author

  P. Attali AuthorId : 1175949
Author

  J. M. Molina AuthorId : 174681
Author

  Y. Bacq AuthorId : 1175950
Author

  A. Tran AuthorId : 577752
Author

  J. D. Grangé AuthorId : 1175951
Author

  F. Zoulim ^{9, 10} AuthorId : 342588
Author

  H. Fontaine ¹¹ AuthorId : 244083
Author

  I. Bertucci AuthorId : 1175952
Author

  M. Bouvier-Alias AuthorId : 1175953
Author

  F. Carrat ^{12, 13} AuthorId : 237640
Author IdHAL : fabrice-carrat ResearcherId : http://www.researcherid.com/rid/P-6177-2017 ORCID : https://orcid.org/0000-0002-8672-7918

  Y Benhamou AuthorId : 1175954
Author